Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026
Rhea-AI Summary
Cue Biopharma (Nasdaq: CUE) will present new preclinical data on lead candidate CUE-401 at IMMUNOLOGY2026 in Boston, April 15-19, 2026. The poster describes a bifunctional TGF-beta/IL-2 fusion that promotes antigen-specific FOXP3+ iTreg expansion, supporting potential to restore immune homeostasis.
Positive
- None.
Negative
- None.
News Market Reaction – CUE
In the Apr 15 session, CUE gained 65.37%, reflecting a significant positive market reaction. Argus tracked a peak move of +97.6% during that session. Argus tracked a trough of -2.7% from its starting point during tracking. Our momentum scanner triggered 80 alerts that day, indicating high trading interest and price volatility. Trading volume was very high at 3.1x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 08 | Collaboration milestone | Positive | +45.5% | $7.5M preclinical milestone from Boehringer Ingelheim collaboration and license. |
| Mar 27 | CEO transition | Neutral | -5.6% | Interim CEO appointment and leadership change focused on advancing CUE-401. |
| Mar 26 | R&D day announcement | Neutral | -5.0% | Announcement of virtual R&D Day to discuss CUE-401 research. |
| Mar 16 | Earnings and updates | Negative | -12.8% | Q4 and 2025 results with collaboration revenue, cash balance, loss, and financing. |
| Mar 09 | Scientific meeting data | Positive | +0.4% | New in vitro CUE-401 data presented at WIRM 2026 on immune modulation. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News on partnerships and scientific data for CUE-401 often led to positive or modest moves, while corporate and financial updates have more frequently coincided with downside pressure.
Over recent months, Cue Biopharma has highlighted multiple developments around lead autoimmune candidate CUE-401 and strategic collaborations. A $7.5M preclinical milestone tied to Boehringer Ingelheim on Apr 8, 2026 was followed by a strong +45.48% move. Earlier in March, announcements on a virtual R&D day, new in vitro data at WIRM 2026, and 2025 earnings with financing actions saw share price declines between -5.03% and -12.84%. A CEO transition on Mar 27, 2026 also coincided with a negative reaction, underscoring sensitivity to leadership and funding signals.
Key Terms
tgf-beta medical
il-2 medical
foxp3+ tregs medical
t regulatory cells medical
cd4+ t cells medical
interleukin-2 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that it will present new preclinical data for its lead autoimmune and inflammatory disease candidate, CUE-401, as part of a poster at IMMUNOLOGY2026, the annual meeting of the American Association of Immunologists (AAI) taking place in Boston, Massachusetts, April 15-19, 2026.
Poster Presentation Details:
Title: CUE-401: A Novel Bifunctional TGF-beta/IL-2 Fusion Protein that Induces Selective Expansion of Functional, Stable FOXP3+ Tregs for the Treatment of Autoimmunity
Presenter: Natasha M. Girgis, Director, Translational Pharmacology
Date and Time: Saturday, April 18, 2026, 11:30 a.m. – 12:30 p.m. EDT
Poster Number: 733
Session: Therapeutics for Autoimmune Diseases II
Location: Exhibit Hall
As part of the presentation, Dr. Girgis will discuss new in vivo data that supports CUE-401’s ability to induce FOXP3+ antigen-specific induced T regulatory cells (iTregs) from FOXP3- conventional CD4+ T cells through the coordinated delivery of TGF-β and interleukin-2 (IL-2) signals. This new and promising preclinical data supports CUE-401’s therapeutic potential to restore immune homeostasis in autoimmune and inflammatory diseases.
About CUE-401
CUE-401 is a novel bifunctional therapeutic that incorporates an innovative TGF-beta breathing-mask moiety with Cue Biopharma’s clinically validated interleukin-2 (IL-2) mutein in a single injectable biologic. The design of CUE 401 was inspired by Nobel Prize winning science in 2025 for the role of IL-2 and TGF-beta as essential components in helping establish immune tolerance by regulating FOXP3 signaling. CUE-401 is designed to promote immune regulation and tolerance by three complementary mechanisms: 1. Direct regulation of proinflammatory mechanisms by TGF-beta, 2. Expansion of existing Tregs by IL-2, and 3. Conversion of FOXP3- conventional CD4+ T cells into FOXP3+ induced Tregs through the coordinated provision of TGF-beta and IL-2 signals, both of which are required for the de novo induction of FOXP3 expression.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT® (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system without the adverse effects of broad systemic immune modulation. CUE-401, the company’s lead autoimmune asset, is designed to act mechanistically both as a regulator of proinflammatory mechanisms, and as a master switch for regulatory T cell (Treg) differentiation to induce tolerance. It is a highly innovative, tolerogenic bifunctional molecule combining a TGF-beta breathing-mask moiety with Cue Biopharma’s clinically validated interleukin 2 (IL-2) mutein in a single injectable biologic.
Headquartered in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the company’s belief regarding the potential benefits and applications of its drug candidates and programs, including the company’s plans to further advance its differentiating Immuno-STAT® platform and lead autoimmune and inflammatory asset, CUE-401; the company’s belief that CUE-401 has the therapeutic potential to restore immune homeostasis in autoimmune and inflammatory diseases; and the company’s business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “promise” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company’s ability to maintain its collaboration with ImmunoScape; the company’s limited operating history, limited cash and a history of losses; the company’s ability to obtain adequate financing to fund its business operations in the near term and successfully remediate its current “going concern” determination that it does not have sufficient capital on hand to continue operations beyond the next twelve months; the company’s ability to achieve profitability; potential setbacks in the company’s research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or the company’s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; its ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including possible effects on the company’s operations and clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company’s ability to obtain adequate financing to fund its business operations in the future and ability to continue as a going concern; the company’s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com
